Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts.

Sridar C, Kenaan C, Hollenberg PF.

Drug Metab Dispos. 2012 Dec;40(12):2256-66. doi: 10.1124/dmd.112.046979.

3.

Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction.

Nirogi R, Palacharla RC, Mohammed AR, Manoharan A, Ponnamaneni RK, Bhyrapuneni G.

Chem Biol Interact. 2015 Mar 25;230:9-20. doi: 10.1016/j.cbi.2015.01.028.

PMID:
25656918
5.

Mechanism-based inactivation of cytochrome P450 2B6 by methadone through destruction of prosthetic heme.

Amunugama HT, Zhang H, Hollenberg PF.

Drug Metab Dispos. 2012 Sep;40(9):1765-70. doi: 10.1124/dmd.112.045971.

6.
7.

Metabolism of N,N',N"-triethylenethiophosphoramide by CYP2B1 and CYP2B6 results in the inactivation of both isoforms by two distinct mechanisms.

Harleton E, Webster M, Bumpus NN, Kent UM, Rae JM, Hollenberg PF.

J Pharmacol Exp Ther. 2004 Sep;310(3):1011-9.

8.

CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.

Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, Greenblatt DJ.

Drug Metab Dispos. 2000 Oct;28(10):1176-83.

9.

Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6.

Sridar C, Kent UM, Notley LM, Gillam EM, Hollenberg PF.

J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.

10.

Thr302 is the site for the covalent modification of human cytochrome P450 2B6 leading to mechanism-based inactivation by tert-butylphenylacetylene.

Lin HL, Zhang H, Pratt-Hyatt MJ, Hollenberg PF.

Drug Metab Dispos. 2011 Dec;39(12):2431-9. doi: 10.1124/dmd.111.042176.

12.

The effect of ritonavir on human CYP2B6 catalytic activity: heme modification contributes to the mechanism-based inactivation of CYP2B6 and CYP3A4 by ritonavir.

Lin HL, D'Agostino J, Kenaan C, Calinski D, Hollenberg PF.

Drug Metab Dispos. 2013 Oct;41(10):1813-24. doi: 10.1124/dmd.113.053108.

13.

Mechanism-based inactivation of human cytochrome P450 2B6 by clopidogrel: involvement of both covalent modification of cysteinyl residue 475 and loss of heme.

Zhang H, Amunugama H, Ney S, Cooper N, Hollenberg PF.

Mol Pharmacol. 2011 Nov;80(5):839-47. doi: 10.1124/mol.111.073783.

14.

Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion.

Hesse LM, von Moltke LL, Shader RI, Greenblatt DJ.

Drug Metab Dispos. 2001 Feb;29(2):100-2.

15.

Inhibition of human CYP2B6 by N,N',N''-triethylenethiophosphoramide is irreversible and mechanism-based.

Richter T, Schwab M, Eichelbaum M, Zanger UM.

Biochem Pharmacol. 2005 Feb 1;69(3):517-24.

PMID:
15652242
18.

Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine.

Richter T, M├╝rdter TE, Heinkele G, Pleiss J, Tatzel S, Schwab M, Eichelbaum M, Zanger UM.

J Pharmacol Exp Ther. 2004 Jan;308(1):189-97.

19.

Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro.

Turpeinen M, Nieminen R, Juntunen T, Taavitsainen P, Raunio H, Pelkonen O.

Drug Metab Dispos. 2004 Jun;32(6):626-31.

20.

Structure-activity relationship and elucidation of the determinant factor(s) responsible for the mechanism-based inactivation of cytochrome P450 2B6 by substituted phenyl diaziridines.

Kobayashi Y, Sridar C, Kent UM, Puppali SG, Rimoldi JM, Zhang H, Waskell L, Hollenberg PF.

Drug Metab Dispos. 2006 Dec;34(12):2102-10.

Supplemental Content

Support Center